Generated by AI
Nexalin Technology, Inc. Common Stock represents an equity interest in Nexalin Technology, Inc., a medical device company focused on neurostimulation products for mental health and related neurological conditions. The company develops noninvasive bioelectronic systems designed to deliver targeted stimulation through headset-based and forehead-mounted devices, with applications in areas such as anxiety, insomnia, depression, substance use disorder, traumatic brain injury, post-traumatic stress disorder, chronic pain, and other brain-health conditions. Nexalin Technology serves clinicians and patients through products intended for use in medical settings and, in some cases, at home under professional guidance. Its product portfolio is centered on neuromodulation therapies that aim to provide drug-free treatment options within the healthcare and medical technology markets. The stock is used by investors to track ownership in a specialized healthcare company operating at the intersection of medical devices, digital health, and neurotechnology.
Website1776 Yorktown
Houston, TX, 77056
United States
The latest articles about NXL.
Results from the randomized, double-blind, sham-controlled TRANSFORM-AD study published in the Journal of Alzheimer's Disease, a recognized international peer-reviewed journal Statistically significant improvement in sleep quality versus sham (p < 0.001) with no serious adverse events; authors describe the study as the first to evaluate high-intensity stimulation for neuropsychiatric symptoms in Alzheimer's disease HOUSTON, TX, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Nexalin Technology, Inc. (Nasdaq:
Summary of Oct 8's posts. Generated by AI.
Summary of Oct 1's posts. Generated by AI.
Summary of Oct 5's posts. Generated by AI.
Investors talking about NXL also mention these. Each card shows that asset’s own numbers for the past 24 hours.
Valuation and earnings.